1. In Vivo
  2. >>Deal-Making

Punctal Plug Can’t Keep QLT Afloat

Five years ago, QLT Inc. charged in hard and snapped up an experimental drug-eluting punctal plug technology created by incubator ForSight Labs LLC. At the time, we reported in START-UP that the punctal plug – designed to deliver drugs directly into the eye – might make or break the company. Looks like it was the latter. Last month, QLT’s newly elected board of directors instituted a broad reshuffling of the company. The board cut the work force by 68% and it intends to divest the still-experimental punctal plug technology, hoping to sell the line outright or spin it out into another entity.

Five years ago, publicly traded QLT Inc.charged in hard and snapped up an experimental drug-eluting punctal plug technology created by incubator ForSight Labs LLC. The technology had only existed a year, but QLT’s CEO Bob Butchofsky was a believer, agreeing to pay $42 million up front for the untested technology, a nice return for investors who had committed less than $5 million to the project. [See Deal] At the time, we reported in START-UP that the punctal plug – designed to deliver drugs directly into the eye – might make or break the company. (See Also see "Happy Return: QLT Bets Big on ForSight Plug " - Medtech Insight, 1 November, 2007..)

Looks like it was the latter. Last month, QLT’s newly elected board of directors instituted a broad reshuffling of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.